Home » Blog » Remibrutinib Treatment Has No Impact on Blood Counts in Patients With Chronic Spontaneous Urticaria: Results From Phase 2b 52-week Extension Study Results
Remibrutinib Treatment Has No Impact on Blood Counts in Patients With Chronic Spontaneous Urticaria: Results From Phase 2b 52-week Extension Study Results
4 Views
SaveSavedRemoved 0
Remibrutinib (LOU064), a extremely selective oral Bruton’s tyrosine kinase inhibitor, has proven efficacy and a good security profile in sufferers with power spontaneous urticaria in a previous core research. Right here, we report change from baseline (CFB) in blood cell counts from the Section 2b 52-week extension research.
Trending Merchandise
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$25.00
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$29.71
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$32.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$13.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$17.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$7.85
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$8.83
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$45.40
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$9.99
Added to wishlistRemoved from wishlist 0
Carlyle Cat’s Claw Capsules 1000mg | 180 Count | Uncaria Tomentosa | Non-GMO, Gluten Free Supplement
Added to wishlistRemoved from wishlist 0
$15.28